Crescent Capital BDC: Valuation Is Cheap, but the Book Is Shrinking

Crescent Capital BDC (CCAP) closed Thursday near $9.93, down roughly 30% so far this year. For a lender that states its net asset value at $17.82 a share, the market's arithmetic collapses to one line: investors are pricing the stock at about 56 cents per dollar of declared book value, a discount of roughly 44%. That is normally the exact invitation a business-development-company investor waits for. The question this stock forces is whether the discount is a bargain or a warning, and the answer hinges on which direction the book itself is moving.

That is precisely the point BofA Securities raised when it cut Crescent to Neutral from Buy on Thursday, trimming its price target from $13 to $10.25 on the company's net asset value discount and what it called "current credit stress." The downgrade is worth reading as a mechanism, not a headline: for a BDC, "cheap to book" only matters if the book holds still. Crescent's has not been holding still.

Why the discount keeps widening

A BDC's stock is a claim on the asset pool sitting behind it. A wide gap between price and net asset value usually signals one of two things: a market that has overreacted, or a book that will not hold at its stated value. Crescent has spent a year demonstrating the second.

Net asset value per share fell from $19.55 a year ago to $18.27 at the end of March and then to $17.82 at the end of June. Net investment income — the cash the portfolio throws off per share, and the engine behind the dividend — slid to $0.36 in the second quarter from $0.42 the prior quarter and $0.46 a year earlier. The share of that income the board is willing to pay out fell with it: the base dividend was cut to $0.34 a share. When the number on the balance sheet, the income it generates, and the dividend it supports are all stepping down together, a discount that climbs as the stock falls is less an opportunity than a re-pricing of a smaller asset.

The credit marks behind the slide

The deterioration is not hypothetical. Crescent booked a net loss in the first quarter and again in the second, the latter driven by realized losses. Chief executive Jason Breaux tied the quarter's NAV decline directly to credit issues "under active management", and the portfolio's pain has concentrated in its healthcare non-accruals. When a BDC's stated book value is being marked down by its own manager, the market's skepticism is not necessarily paranoia — it may be a correct bet that further marks are coming.

Against that, there is a genuine, if thin, bull case hiding inside the bear report. Non-accruals actually improved during the quarter, falling from 5.7% to 4.8% of debt investments at cost, with no new non-accruals added, and management said it completed three restructurings with minimal net impact on NAV. Net investment income of $0.36 still covered the $0.34 base dividend. That is the evidence for "the worst may be in." It is real but narrow — the investment-income cover is barely a dollar of earnings for each dollar of dividend, and leverage is elevated at 1.42x debt-to-equity, above the company's target range, even as management expects it to normalize in the second half.

Too early to call it cheap

The temptation here is to treat the 44% gap to book as fear to buy. That is the trap the downgrade is really flagging. The discount is genuine — Crescent is not hiding assets behind the multiple — but it discounts a denominator that is still shrinking, and thin dividend coverage leaves little cushion if net investment income slides another step. This reads as too early rather than too cheap: value is only proven if the book stops falling and the cut dividend holds, and the next two quarters are the proof window. Watch whether NAV and net investment income stabilize and whether non-accruals stay out of the new-credit column. Until then, a deep discount on a moving book is a question, not yet an answer.